Skip to main content
Premium Trial:

Request an Annual Quote

Pronto Diagnostics Plans to Integrate FDNA's Phenotypic Analysis Into Its Genetic Tests

NEW YORK (GenomeWeb) – Israeli molecular diagnostics firm Pronto Diagnostics recently said that it has combined its suite of genetic tests with FDNA's Face2Gene phenotyping applications.

Pronto offers both next-generation sequencing-based gene panels and exome testing as well as single-gene molecular tests.

FDNA's Face2Gene technology uses facial analysis, deep learning, and artificial intelligence to improve molecular diagnostics. It enables clinicians to integrate phenotypic data into genetic testing pipelines in order to improve the chances of making a diagnosis.

"As a deep learning platform, Face2Gene grows in capabilities and disease understanding with increased use," FDNA CEO Dekel Gelbman said in a statement.

Pronto CEO Nir Navot added that the firm is "dedicated to bringing patients answers to complex health questions, and this new technology will bring about those answers more effectively and efficiently."

The Scan

Could Cost Billions

NBC News reports that the new Alzheimer's disease drug from Biogen could cost Medicare in the US billions of dollars.

Not Quite Sent

The Biden Administration likely won't meet its goal of sending 80 million SARS-CoV-2 vaccine doses abroad by the end of the month, according to the Washington Post.

DTC Regulation Proposals

A new report calls on UK policymakers to review direct-to-consumer genetic testing regulations, the Independent reports.

PNAS Papers on Mosquito MicroRNAs, Acute Kidney Injury, Trichothiodystrophy

In PNAS this week: microRNAs involved in Aedes aegypti reproduction, proximal tubule cell response to kidney injury, and more.